NeuroNascent Aims to Reverse Neurodegenerative Damage
By Marie Powers
Thursday, September 13, 2012
A slew of recent failures in Alzheimer's disease (AD) could prove providential for NeuroNascent Inc., which has ambitious plans to halt and potentially reverse a range of neurodegenerative diseases.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.